for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zhejiang Huahai Pharmaceutical Co., Ltd.

600521.SS

Latest Trade

17.12CNY

Change

-0.30(-1.72%)

Volume

15,020,863

Today's Range

17.07

 - 

17.45

52 Week Range

9.80

 - 

19.81

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
17.42
Open
17.34
Volume
15,020,863
3M AVG Volume
438.87
Today's High
17.45
Today's Low
17.07
52 Week High
19.81
52 Week Low
9.80
Shares Out (MIL)
1,322.37
Market Cap (MIL)
23,432.41
Forward P/E
28.69
Dividend (Yield %)
--

Next Event

Zhejiang Huahai Pharmaceutical Co Ltd Annual Shareholders Meeting

Latest Developments

更多

Zhejiang Huahai Pharmaceutical Sees 9-Month Net Profit Up 96-115% Y/Y

Zhejiang Huahai Pharmaceutical's Senior Executive Cai Minda Passes Away Due To Illness

U.S. FDA Releases Warning Letter To Zhejiang Huahai Pharmaceutical

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zhejiang Huahai Pharmaceutical Co., Ltd.

ZHEJIANGHUAHAIPHARMACEUTICALCO., LTD is a China-based company, principally engaged in the manufacture and distribution of active pharmaceutical ingredients (APIs), intermediates and preparations. The Company's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine hydrochloride tablets, risperidone tablets, fosinopril sodium tablets, as well as irbesartan and hydrochlorothinzide tablets, among others. The Company also provides related technical support services. The Company distributes its products in domestic and overseas markets.

Industry

Biotechnology & Drugs

Contact Info

Xunqiao, Linhai City

+86.576.85991096

http://en.huahaipharm.com

Executive Leadership

Jun Du

Vice Chairman of the Board

Mei Zhang

Chief Financial Officer, Finance Director

Baohua Chen

General Manager, Director

Yong Hua Zhu

Deputy General Manager, Secretary of the Board, Director

Qimao Chen

Deputy General Manager

Key Stats

4.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

4.1K

2017

5.0K

2018

5.1K

2019(E)

5.8K
EPS (CNY)

2016

0.588

2017

0.744

2018

0.086

2019(E)

0.618
Price To Earnings (TTM)
61.23
Price To Sales (TTM)
4.45
Price To Book (MRQ)
4.22
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
84.40
LT Debt To Equity (MRQ)
8.89
Return on Investment (TTM)
6.18
Return on Equity (TTM)
3.67

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up